Relay Therapeutics (RLAY) Income towards Parent Company (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Income towards Parent Company data on file, last reported at -$79.1 million in Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 1.49% year-over-year to -$79.1 million in Q1 2026; TTM through Mar 2026 was -$262.4 million, a 64.77% increase from a year earlier, with the FY2025 full-year figure at -$756.2 million, up 1.75% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$79.1 million, down from -$35.1 million in the prior quarter.
• Over the last five years, Income towards Parent Company for RLAY reached as high as -$35.1 million in Q4 2025 and fell as low as -$484.9 million in Q4 2024.
• Historically, Income towards Parent Company has averaged -$105.8 million across 5 years, with a median of -$82.7 million in 2024.
• Across the five-year window, Income towards Parent Company plunged 443.15% in 2024 and surged 92.76% in 2025, its largest moves.
• Year by year, Income towards Parent Company stood at -$75.1 million in 2022, then dropped by 18.93% to -$89.3 million in 2023, then plunged by 443.15% to -$484.9 million in 2024, then jumped by 92.76% to -$35.1 million in 2025, then sank by 125.53% to -$79.1 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were -$79.1 million in Q1 2026, -$35.1 million in Q4 2025, and -$74.2 million in Q3 2025.